Course Description: The diagnosis and management of Male Lower Urinary Tract Symptoms (mLUTS) and benign prostatic hyperplasia (BPH) has evolved dramatically over the past 5 years with changing algorithms. The AUA BPH Guidelines were revised in 2018 focusing primarily on diagnostic algorithms and surgical modalities. The 2020 Guidelines will incorporate recommendations about medical therapies. This course is designed to review, discuss and develop a coherent diagnostic and treatment strategy for men with mLUTS. This will include risk factors such as obesity, the role of both AUA and international guidelines, established algorithms, medical therapy with both mono and combination therapy with agents such as alpha blockers, antimuscarinics, beta - 3 agonists, 5-alpha reductase inhibitors, PDE - 5 inhibitors and surgical options including minimally invasive (UroLift / Rezum) and surgical options (electrosurgical, laser, aquablation). In addition, how these agents dovetail with sexual function and testosterone replacement therapy will be highlighted. Finally, pharmaco economics and the impact of long term therapy as well as surgical outcomes will be debated.

Learning Objectives: Upon completion of this activity, participants will be able to:

1. Recognize the various medical agents available to treat mLUTS and their appropriate use.

2. Identify common aspects of metabolic dysfunction and its relationship to voiding and sexual health.

3. Utilize, understand and employ the AUA Guidelines for BPH.

4. Employ the proper diagnostic algorithms to manage men with LUTS with medical, minimally invasive and surgical therapies.